RESEARCH FUND OF THE HADASSAH MEDICAL ORGANIZATION (R.A)

Their core work

Hadassah Medical Organization's research fund supports clinical and translational biomedical research at one of Israel's leading university hospitals. Their H2020 work spans advanced medical imaging (hyperpolarized MRI using diamond nanoparticles), clinical oncology trials (glioma treatment), single-cell genomics of the pancreas, and adoptive T cell therapy for cancer. They bridge hospital-based clinical expertise with participation in European research training and innovation consortia.

What they specialise in

How they've shifted over time

In their earlier H2020 participation (2016-2018), Hadassah engaged in physics-adjacent medical imaging research (hyperpolarized MRI, quantum technologies) alongside clinical oncology trials. From 2020 onward, their focus shifted decisively toward cellular and immunological approaches — single-cell pancreas mapping and T cell therapy optimization. This reflects a broader institutional move from imaging diagnostics toward cell-level therapeutic interventions.

Hadassah is moving toward cancer immunotherapy and cell-based treatments, making them a relevant partner for future projects in adoptive cell therapy, immuno-oncology, and personalized medicine.

How they like to work

Hadassah has participated exclusively as a consortium partner across all four projects, never as coordinator — consistent with a hospital research fund contributing clinical expertise and patient access to larger European consortia. With 46 unique partners across 13 countries, they are well-networked and comfortable working in diverse, multinational teams. Their role is typically that of a clinical or domain specialist embedded within broader research efforts.

Hadassah has collaborated with 46 distinct partners across 13 countries, indicating broad European reach for an Israeli institution. Their network spans clinical, academic, and training consortia rather than being concentrated in a single geographic cluster.

What sets them apart

As a research fund of one of Israel's most prominent teaching hospitals, Hadassah offers something many European academic partners cannot: direct clinical infrastructure, patient cohorts, and regulatory experience for translational medical research. Their combination of oncology trial execution (CLINGLIO), advanced imaging (HYPERDIAMOND), and emerging immunotherapy expertise (T-OP) makes them a versatile biomedical partner. For consortium builders, they provide a non-EU Associated Country perspective with strong clinical credibility.

Highlights from their portfolio

• HYPERDIAMOND
  Largest single grant (EUR 427,750) combining quantum technologies with medical imaging — an unusual interdisciplinary bridge between physics and diagnostics.
• T-OP
  Most recent project (2021-2025) and a Marie Curie training network, signalling Hadassah's investment in next-generation cancer immunotherapy researchers.
• CLINGLIO
  A Phase IIB clinical trial for malignant glioma — demonstrates capacity to participate in advanced-stage drug development within EU consortia.